Brandt A, Schultheiss C, Klinghammer K, Schafhausen P, Busch C-J, Blaurock M, Hinke A, Tometten M, Dietz A, Müller-Richter U, et al. Tolerability and efficacy of the cancer vaccine UV1 in patients with recurrent or metastatic PD-L1 positive head and neck squamous cell carcinoma planned for first-line treatment with pembrolizumab - the randomized phase 2 FOCUS trial. Front Oncol. 2024;14:1283266.